



## Marinomed to present at Munich capital market conference (MKK)

*Marinomed presentation at Münchner Kapital Konferenz on 7 December, 15:05 CET*

**Korneuburg, Austria, 01 December 2021** – Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, will be attending MKK – Münchner Kapitalmarkt Konferenz, an investor and capital market conference connecting public companies and investors.

### **32. MKK – Münchner Kapitalmarkt Konferenz Online**

#### **7-8 December 2021, virtual format – Zoom conference**

**Speakers:** Dr. Andreas Grassauer, Chief Executive Officer, Pascal Schmidt, Chief Financial Officer, and Stephanie Kniep, Investor Relations.

**Date:** Tuesday, 7 December 2021, 15:05-15:40 pm, Room GBC II

Marinomed will also be available for 1on1 meetings for a year-end update with interested parties. Further information on the conference website: <https://mkk-konferenz.de/>

### **About Marinomed Biotech AG**

Marinomed Biotech AG is an Austrian science-based biotech company with globally marketed therapeutics. Marinomed focuses on the development of innovative products based on two patent-protected technology platforms. The Marinosolv<sup>®</sup> technology increases the solubility and bioavailability of compounds that are hardly soluble in aqueous formulations. Under the brand Solv<sup>4U</sup>, Marinomed provides formulation development based on the Marinosolv<sup>®</sup> technology for external partners. The Carragelose<sup>®</sup> platform comprises innovative patent-protected products targeting viral infections of the respiratory tract and may also reduce the risk of an infection with SARS-CoV-2. Carragelose<sup>®</sup> is used as a virus blocker in nasal sprays, throat sprays, and lozenges, which are sold via international partners in over 40 countries. Marinomed, Marinosolv<sup>®</sup> and Carragelose<sup>®</sup> are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only. The company is based in Korneuburg, Austria, and listed on the Prime Market of the Vienna Stock Exchange (VSE:MARI). Further information is available at <https://www.marinomed.com>.

#### **Marinomed Biotech AG**

Stephanie Kniep, IR  
Hovengasse 25, 2100 Korneuburg, Austria  
T +43 2262 90 300 226  
E-mail: [ir@marinomed.com](mailto:ir@marinomed.com)  
<http://www.marinomed.com>

#### **International Media Contact**

MC Services AG  
Dr. Brigitte Keller, Dr. Regina Lutz  
T +49 89 210228 0  
**UK:** Shaun Brown  
M: +44 7867 515 918  
E-mail: [marinomed@mc-services.eu](mailto:marinomed@mc-services.eu)

**Disclaimer**

This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and “target”. Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise.